Form 4: Apellis Director Wheeler Receives Equity Awards

Apellis Pharmaceuticals director Craig A. Wheeler was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026, as part of his compensation.

Summary

• Craig A. Wheeler, a director at Apellis Pharmaceuticals, Inc. (APLS), received equity awards on January 1, 2026.
• He was granted 7,961 restricted stock units (RSUs) of common stock, which will fully vest on January 1, 2027, or upon later termination of his service as a director at his election, contingent on his continued service.
• He was also granted 14,684 stock options with an exercise price of $25.12. These options vest quarterly from the grant date, subject to his continued service as a director, and expire on December 31, 2033.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Following these transactions, Mr. Wheeler beneficially owns 24,444 shares of common stock and 14,684 stock options directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing reports routine director compensation, which is a standard corporate governance practice. It indicates continued commitment from a director and aligns their interests with shareholders, which is generally positive, but does not reflect operational performance.

Positives

• The equity grants align the director's financial interests with the long-term performance and shareholder value of Apellis Pharmaceuticals.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged and compliant transaction, reducing concerns about opportunistic insider trading.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions related to compensation.

Future Outlook

This filing does not contain specific forward-looking statements or guidance beyond the vesting schedules of the granted equity awards.

Industry Context

The granting of equity awards to directors is a standard practice in the biotechnology and pharmaceutical industry, aiming to align leadership incentives with long-term company performance and shareholder interests. Apellis Pharmaceuticals, like many peers, uses such compensation structures to attract and retain experienced board members.

Comparison to Industry Standards

• The structure of director compensation, including a mix of restricted stock units and stock options, is consistent with common practices among publicly traded biotechnology companies of similar market capitalization to Apellis Pharmaceuticals.
• The vesting schedules (one-year for RSUs, quarterly for options) are typical for director equity grants, designed to ensure continued service and long-term commitment.
• The exercise price of $25.12 for the options, likely the closing price on the grant date, is standard for at-the-money option grants.

Related Party Transactions

• The grant of restricted stock units and stock options to a director constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The restricted stock units are expected to fully vest on January 1, 2027, subject to continued service.
• The stock options will vest quarterly from January 1, 2026, subject to continued service, and expire on December 31, 2033.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not provide information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals. While the grants align director interests with shareholders, they do not reflect operational performance or strategic shifts that would warrant a change in investment recommendation based solely on this document. Investors should continue to hold and monitor the company's financial results and pipeline developments.

Keywords

Apellis Pharmaceuticals, APLS, Craig Wheeler, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Rule 10b5-1